Physician profile
Christopher Baker
NPI 1558904946
$1,428.31
in general payments reported to CMS, 2019-2025
21 companies · $65.10 in 2025
The $65.10 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $375 · 2022: $431 · 2023: $449 · 2024: $109 · 2025: $65.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $623.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $622.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $279.40 | 2021-2023 | Wegovy, Saxenda |
| Abbvie INC. | $225.52 | 2021-2025 | |
| Lilly USA, LLC | $167.35 | 2021-2025 | Mounjaro, Trulicity, Emgality |
| Amgen INC. | $152.90 | 2021-2023 | Repatha, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.82 | 2021-2025 | Synjardy, Jardiance |
| Glaxosmithkline, LLC. | $87.12 | 2021-2023 | Trelegy Ellipta |
| Daiichi Sankyo INC. | $69.15 | 2021-2022 | |
| Pfizer INC. | $64.85 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $46.19 | 2022 | |
| Amarin Pharma, INC. | $39.74 | 2021 | |
| Sunovion Pharmaceuticals INC. | $31.54 | 2021 | |
| Dexcom, INC. | $27.69 | 2021 | |
| Inari Medical, INC. | $25.58 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Exact Sciences Corporation | $20.24 | 2023 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.35 | 2023 | Xifaxan, Trulance |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $14.67 | 2023 | Contrave, Onzetra Xsail |
| Phathom Pharmaceuticals, INC. | $14.67 | 2024 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $14.24 | 2022 | |
| Ge Healthcare | $12.69 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $12.20 | 2021 | |
| Sanofi-Aventis U.S. LLC | $11.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.